Tech Company Financing Transactions
BigHat Biosciences Funding Round
On 7/20/2022, BigHat Biosciences landed $75 million in Series B funding from Section 32, 8VC and AME Cloud Ventures.
Transaction Overview
Company Name
Announced On
7/20/2022
Transaction Type
Venture Equity
Amount
$75,000,000
Round
Series B
Investors
Section 32 (Lead Investor) (Steve Kafka)
Andreessen Horowitz (Vineeta Agarwala)
Proceeds Purpose
We will be used to scale the capacity of MillinerTM, an integrated AI/ML- wet lab platform, advance therapeutic programs toward human clinical trials, aggressively hire drug discovery and development talent and to accelerate strategic collaborations with flagship partners.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
733 Industrial Rd.
San Carlos, CA 94070
USA
San Carlos, CA 94070
USA
Phone
Undisclosed
Website
Email Address
Overview
BigHat's mission is to improve human health by making it far easier to design advanced, next-generation antibody therapeutics. Our AI-enabled experimental platform integrates a high-speed characterization or wet lab with machine learning technologies to speed the antibody engineering process.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mark DePristo
Chief Scientific Officer
Peyton Greenside
VP - Bus. Development
Elizabeth Schwarzbach
VP - Engineering
Eddie Abrams
Browse more venture capital transactions:
Prev: 7/20/2022: Proteus Motion venture capital transaction
Next: 7/20/2022: Passionfruit venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on all VC transactions involving tech companies. All VC database entries reported here come from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs